Naoki Nishio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Naoki Nishio has a total of 334 co-authors. Here are the top co-authors by number of shared publications:
Michihiko Sone
Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine , Nagoya 466-8550
22 shared publicationsShayan Fakurnejad
16 shared publicationsYasushi Fujimoto
15 shared publicationsAkihisa Wada
Department of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya, Japan
14 shared publicationsNobuaki Mukoyama
Department of Otorhinolaryngology Nagoya University Graduate School of Medicine Nagoya Japan
14 shared publications- Nynke S. van Den Berg
Department of Research, Intuitive Surgical Inc., Sunnyvale, California
14 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Elsevier in World Neurosurgery
- Vol. 216, 125419
Tailoring Surgical Strategy for Advanced Lateral Skull Base Malignancies: Anatomical Constraints and Histological Limits in Margin Control
- 15 October 2026
- Published by Elsevier in World Neurosurgery
- Vol. 216, 125419
Open AccessTailoring Surgical Strategy for Advanced Lateral Skull Base Malignancies: Anatomical Constraints and Histological Limits in Margin Control
- Open Access
- 20 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (27) , 2602-2613
Darolutamide Alone and in Combination With Goserelin in Androgen Receptor–Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial
PURPOSE: Salivary gland carcinoma (SGC), particularly salivary duct carcinoma (SDC), is a rare and aggressive malignancy with no standard systemic treatment. Androgen receptor (AR) expression is frequently detected in SDC, which suggests inhibition of the AR pathway as a therapeutic strategy. We conducted a prospective phase II trial of the efficacy and safety of darolutamide, a second-generation AR signaling inhibitor, as monotherapy or in combination with goserelin, in patients with AR-positive unresectable locally advanced (LA) or recurrent/metastatic (R/M) SGC. METHODS: DISCOVARY was a multicenter, single-arm, phase II trial conducted in Japan. Patients with unresectable LA or R/M AR-positive SGC were enrolled into two sequential cohorts, a monotherapy cohort (darolutamide 600 mg orally twice daily) and a combination cohort (darolutamide plus goserelin 3.6 mg subcutaneously once every 28 days). The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), safety, and health-related quality of life. RESULTS: Fifty-seven patients were enrolled (monotherapy, n = 24; combination, n = 33). In the monotherapy cohort, the confirmed ORR was 8.3% (90% CI, 1.5 to 24.0) and the median PFS was 5.7 months. In the combination cohort, ORR was 45.2% (90% CI, 29.7 to 61.3) and the median PFS was 13.1 months. Twelve-month OS rates were 91.3% and 87.0%, respectively. Most adverse events were grade 1 or 2 in severity, with no treatment-related deaths. Quality of life was preserved. No clear association between AR expression level or Ki-67 index and treatment response was evident in exploratory analysis. CONCLUSION: Darolutamide demonstrated antitumor activity in AR-positive SGC, with numerically more favorable outcomes with goserelin. Darolutamide plus goserelin may represent a chemotherapy-sparing option in this rare malignancy.
- 20 September 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (27) , 2602-2613
Open AccessDarolutamide Alone and in Combination With Goserelin in Androgen Receptor–Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial
PURPOSE: Salivary gland carcinoma (SGC), particularly salivary duct carcinoma (SDC), is a rare and aggressive malignancy with no standard systemic treatment. Androgen receptor (AR) expression is frequently detected in SDC, which suggests inhibition of the AR pathway as a therapeutic strategy. We conducted a prospective phase II trial of the efficacy and safety of darolutamide, a second-generation AR signaling inhibitor, as monotherapy or in combination with goserelin, in patients with AR-positive unresectable locally advanced (LA) or recurrent/metastatic (R/M) SGC. METHODS: DISCOVARY was a multicenter, single-arm, phase II trial conducted in Japan. Patients with unresectable LA or R/M AR-positive SGC were enrolled into two sequential cohorts, a monotherapy cohort (darolutamide 600 mg orally twice daily) and a combination cohort (darolutamide plus goserelin 3.6 mg subcutaneously once every 28 days). The primary end point was objective response rate (ORR). Secondary end points included progression-free survival (PFS), overall survival (OS), safety, and health-related quality of life. RESULTS: Fifty-seven patients were enrolled (monotherapy, n = 24; combination, n = 33). In the monotherapy cohort, the confirmed ORR was 8.3% (90% CI, 1.5 to 24.0) and the median PFS was 5.7 months. In the combination cohort, ORR was 45.2% (90% CI, 29.7 to 61.3) and the median PFS was 13.1 months. Twelve-month OS rates were 91.3% and 87.0%, respectively. Most adverse events were grade 1 or 2 in severity, with no treatment-related deaths. Quality of life was preserved. No clear association between AR expression level or Ki-67 index and treatment response was evident in exploratory analysis. CONCLUSION: Darolutamide demonstrated antitumor activity in AR-positive SGC, with numerically more favorable outcomes with goserelin. Darolutamide plus goserelin may represent a chemotherapy-sparing option in this rare malignancy.
- Open Access
- 29 July 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (11) , 1443-1449
A multicenter randomized phase III trial to evaluate the value of omission of elective neck dissection for T3–T4aN0 laryngeal cancer: JCOG2407 (JALNECK)
Total laryngectomy with paratracheal dissection and elective lateral neck dissection (ELND) is the standard surgical procedure for T3–T4aN0 laryngeal cancer. However, ELND is associated with increased surgical invasiveness, higher risk of postoperative complications, and long-term functional impairment. Although previous studies suggest that ELND omission may reduce postoperative complications, including pharyngocutaneous fistulas and deterioration in quality of life (QOL), its impact on prognosis remains controversial. Therefore, we designed a multicenter, randomized phase III trial (JCOG2407) to confirm the non-inferiority of total laryngectomy with paratracheal dissection alone compared to surgery including ELND for T3–T4aN0 laryngeal cancer. The primary endpoint is overall survival. The secondary endpoints include short-term outcomes, postoperative complications, functional assessments, and QOL. A total of 280 patients from 39 institutions will be enrolled over 5 years. This trial has been registered with the Japan Registry of Clinical Trials (study number: jRCT1030250729).
- 29 July 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (11) , 1443-1449
Open AccessA multicenter randomized phase III trial to evaluate the value of omission of elective neck dissection for T3–T4aN0 laryngeal cancer: JCOG2407 (JALNECK)
Total laryngectomy with paratracheal dissection and elective lateral neck dissection (ELND) is the standard surgical procedure for T3–T4aN0 laryngeal cancer. However, ELND is associated with increased surgical invasiveness, higher risk of postoperative complications, and long-term functional impairment. Although previous studies suggest that ELND omission may reduce postoperative complications, including pharyngocutaneous fistulas and deterioration in quality of life (QOL), its impact on prognosis remains controversial. Therefore, we designed a multicenter, randomized phase III trial (JCOG2407) to confirm the non-inferiority of total laryngectomy with paratracheal dissection alone compared to surgery including ELND for T3–T4aN0 laryngeal cancer. The primary endpoint is overall survival. The secondary endpoints include short-term outcomes, postoperative complications, functional assessments, and QOL. A total of 280 patients from 39 institutions will be enrolled over 5 years. This trial has been registered with the Japan Registry of Clinical Trials (study number: jRCT1030250729).
- Open Access
- 17 July 2026
- Published by Elsevier in Auris Nasus Larynx
- Vol. 53 (5) , 725-729
The laryngofissure approach for near-infrared photoimmunotherapy in laryngeal cancer: A novel larynx-preservation strategy
- 17 July 2026
- Published by Elsevier in Auris Nasus Larynx
- Vol. 53 (5) , 725-729
Open AccessThe laryngofissure approach for near-infrared photoimmunotherapy in laryngeal cancer: A novel larynx-preservation strategy
- 26 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (27) , 2574-2581
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer
The interim analysis of JCOG1008 demonstrated that chemoradiotherapy with cisplatin 40 mg/m 2 once a week for seven cycles (weekly cisplatin) was noninferior in terms of overall survival (OS) compared with chemoradiotherapy with cisplatin 100 mg/m 2 once every 3 weeks for three cycles (3-weekly cisplatin) for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). This report presents the long-term follow-up results of JCOG1008. In this phase II/III trial, patients with postoperative high-risk LA-SCCHN were randomly assigned to receive either chemoradiotherapy with 3-weekly cisplatin or with weekly cisplatin. A total of 261 patients were enrolled. At the final analysis, with a median follow-up of 5.6 years, 5-year OS was 58.7% in the 3-weekly arm and 71.2% in the weekly arm (hazard ratio, 0.76 [95% CI, 0.52 to 1.12 [<1.32]]), confirming the noninferiority of the weekly regimen. Both 5-year relapse-free survival (RFS) and 5-year local RFS were numerically better in the weekly arm. No late adverse event showed more than a 10% difference between the two arms. In conclusion, 5-year follow-up confirmed that chemoradiotherapy with weekly cisplatin is noninferior in OS to chemoradiotherapy with 3-weekly cisplatin in patients with postoperative high-risk LA-SCCHN. These results further support the use of weekly cisplatin plus radiotherapy as a reasonable alternative for this patient population.
- 26 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (27) , 2574-2581
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer
The interim analysis of JCOG1008 demonstrated that chemoradiotherapy with cisplatin 40 mg/m 2 once a week for seven cycles (weekly cisplatin) was noninferior in terms of overall survival (OS) compared with chemoradiotherapy with cisplatin 100 mg/m 2 once every 3 weeks for three cycles (3-weekly cisplatin) for postoperative high-risk locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). This report presents the long-term follow-up results of JCOG1008. In this phase II/III trial, patients with postoperative high-risk LA-SCCHN were randomly assigned to receive either chemoradiotherapy with 3-weekly cisplatin or with weekly cisplatin. A total of 261 patients were enrolled. At the final analysis, with a median follow-up of 5.6 years, 5-year OS was 58.7% in the 3-weekly arm and 71.2% in the weekly arm (hazard ratio, 0.76 [95% CI, 0.52 to 1.12 [<1.32]]), confirming the noninferiority of the weekly regimen. Both 5-year relapse-free survival (RFS) and 5-year local RFS were numerically better in the weekly arm. No late adverse event showed more than a 10% difference between the two arms. In conclusion, 5-year follow-up confirmed that chemoradiotherapy with weekly cisplatin is noninferior in OS to chemoradiotherapy with 3-weekly cisplatin in patients with postoperative high-risk LA-SCCHN. These results further support the use of weekly cisplatin plus radiotherapy as a reasonable alternative for this patient population.
- Open Access
- 1 April 2026
- Published by Elsevier in Auris Nasus Larynx
- Vol. 53 (3) , 375-379
Successful management of near-infrared photoimmunotherapy-induced skin injury using pedicled flap transfer
- 1 April 2026
- Published by Elsevier in Auris Nasus Larynx
- Vol. 53 (3) , 375-379
Open AccessSuccessful management of near-infrared photoimmunotherapy-induced skin injury using pedicled flap transfer
- Open Access
- 8 January 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (2)
Transoral videolaryngoscopic surgery for hypopharyngeal anaplastic metastasis from papillary thyroid carcinoma
We report an extremely rare case of hypopharyngeal metastasis with anaplastic transformation (anaplastic thyroid carcinoma) originating from papillary thyroid carcinoma, demonstrating successful tumor control using minimally invasive transoral surgery combined with targeted therapy. A 78-year-old man with a history of papillary thyroid carcinoma treated with total thyroidectomy and radioactive iodine 10 years earlier presented with sore throat and difficulty swallowing. Fiberoptic examination revealed a 25-mm mass on the posterior hypopharyngeal wall causing airway compromise, necessitating an emergency tracheotomy. Biopsy confirmed hypopharyngeal metastasis with anaplastic thyroid carcinoma. Given his comorbidities (chronic leukemia, severe pulmonary arterial hypertension), he underwent transoral videolaryngoscopic surgery to achieve local tumor control while preserving swallowing function. Postoperative genetic testing detected a BRAF V600E pathogenic variant, leading to treatment with encorafenib and binimetinib, initiated on postoperative day 24. Six months after surgery and targeted therapy, fiberoptic examination and contrast-enhanced computed tomography showed no evidence of recurrent disease; the tracheostomy was closed, and the patient maintained normal swallowing and quality of life. This case illustrates that a surgery-first, function-preserving approach integrated with early molecular-targeted BRAF/MEK inhibition can achieve durable local control and maintain laryngopharyngeal function, even when anaplastic transformation occurs within a hypopharyngeal metastatic focus.
- 8 January 2026
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 4 (2)
Open AccessTransoral videolaryngoscopic surgery for hypopharyngeal anaplastic metastasis from papillary thyroid carcinoma
We report an extremely rare case of hypopharyngeal metastasis with anaplastic transformation (anaplastic thyroid carcinoma) originating from papillary thyroid carcinoma, demonstrating successful tumor control using minimally invasive transoral surgery combined with targeted therapy. A 78-year-old man with a history of papillary thyroid carcinoma treated with total thyroidectomy and radioactive iodine 10 years earlier presented with sore throat and difficulty swallowing. Fiberoptic examination revealed a 25-mm mass on the posterior hypopharyngeal wall causing airway compromise, necessitating an emergency tracheotomy. Biopsy confirmed hypopharyngeal metastasis with anaplastic thyroid carcinoma. Given his comorbidities (chronic leukemia, severe pulmonary arterial hypertension), he underwent transoral videolaryngoscopic surgery to achieve local tumor control while preserving swallowing function. Postoperative genetic testing detected a BRAF V600E pathogenic variant, leading to treatment with encorafenib and binimetinib, initiated on postoperative day 24. Six months after surgery and targeted therapy, fiberoptic examination and contrast-enhanced computed tomography showed no evidence of recurrent disease; the tracheostomy was closed, and the patient maintained normal swallowing and quality of life. This case illustrates that a surgery-first, function-preserving approach integrated with early molecular-targeted BRAF/MEK inhibition can achieve durable local control and maintain laryngopharyngeal function, even when anaplastic transformation occurs within a hypopharyngeal metastatic focus.
- Open Access
A Voice Conversion System from Electrolarynx Speech to Preoperative Patient's Speech for Total Laryngectomy
Laryngectomy is a life‐changing procedure typically performed as a surgical treatment for patients with head and neck cancer. Voice conversion (VC) is a technology that converts one voice into another without changing the linguistic information. Recently, “Save the Voice Project” for patients planning to undergo laryngectomy using our VC technique has been initiated. This study evaluated the speech converted from EL speech using the VC technique in a patient with head and neck cancer who had undergone laryngectomy. Additionally, details of an iPhone/iPad application for voice recording were reported. VC technology would greatly improve the quality of life of patients planning to undergo laryngectomy, especially those with relatively well‐preserved vocal function. To preserve the patient's original normal speech, medical staff should perform voice management before and after laryngectomy, and high‐quality voice recordings are essential.
Open AccessA Voice Conversion System from Electrolarynx Speech to Preoperative Patient's Speech for Total Laryngectomy
Laryngectomy is a life‐changing procedure typically performed as a surgical treatment for patients with head and neck cancer. Voice conversion (VC) is a technology that converts one voice into another without changing the linguistic information. Recently, “Save the Voice Project” for patients planning to undergo laryngectomy using our VC technique has been initiated. This study evaluated the speech converted from EL speech using the VC technique in a patient with head and neck cancer who had undergone laryngectomy. Additionally, details of an iPhone/iPad application for voice recording were reported. VC technology would greatly improve the quality of life of patients planning to undergo laryngectomy, especially those with relatively well‐preserved vocal function. To preserve the patient's original normal speech, medical staff should perform voice management before and after laryngectomy, and high‐quality voice recordings are essential.
- Open Access
- 4 November 2025
- Published by Springer Nature in Research Square
Development and validation of an electrosurgery-compatible simulation task for quantitatively assessing oral cancer resection skills
Background The quality of oral cancer resection is extremely important for patient outcomes, such as local control and survival. However, most current simulators either provide only subjective feedback or are not compatible with electrosurgery. Therefore, we developed an electrosurgical simulation task for oral cancer resection that provides quantitative metrics and investigated its validity. Methods We developed a soft tissue simulation task using a plant-derived model that supports electrosurgery. As quantitative measures demonstrating “ensuring appropriate margins” in oral cancer resection and “maintaining safety” during electrosurgery, we employed nine-directional margin error distance and tumor bed carbonization degree measured using a spectral colorimeter. As validity evidence of the task, 10 expert surgeons completed a questionnaire about the task. In addition, five experts and 12 novices performed the task, and quantitative data obtained from their performance was used for evaluation. Results The replication of oral cancer resection was highly evaluated (4.4 out of 5 points), and quantitative measures for evaluating the skills of surgeons (4.8 out of 5 points) were agreed upon by experts. The internal consistency of the measures was good (Cronbach's alpha: 0.803). Compared to novices, experts had smaller margin errors (0.79 mm vs 2.45 mm), lower carbonization (ΔE: 2.33 vs 8.70), faster resection times, and fewer grasping attempts (all P < 0.0001). Conclusion This user-friendly plant-derived simulation task is compatible with electrosurgery and can quantitatively assess proficiency in oral cancer resection. Using this task is expected to promote early acquisition of tumor resection skills and improve oncological safety.
- 4 November 2025
- Published by Springer Nature in Research Square
Open AccessDevelopment and validation of an electrosurgery-compatible simulation task for quantitatively assessing oral cancer resection skills
Background The quality of oral cancer resection is extremely important for patient outcomes, such as local control and survival. However, most current simulators either provide only subjective feedback or are not compatible with electrosurgery. Therefore, we developed an electrosurgical simulation task for oral cancer resection that provides quantitative metrics and investigated its validity. Methods We developed a soft tissue simulation task using a plant-derived model that supports electrosurgery. As quantitative measures demonstrating “ensuring appropriate margins” in oral cancer resection and “maintaining safety” during electrosurgery, we employed nine-directional margin error distance and tumor bed carbonization degree measured using a spectral colorimeter. As validity evidence of the task, 10 expert surgeons completed a questionnaire about the task. In addition, five experts and 12 novices performed the task, and quantitative data obtained from their performance was used for evaluation. Results The replication of oral cancer resection was highly evaluated (4.4 out of 5 points), and quantitative measures for evaluating the skills of surgeons (4.8 out of 5 points) were agreed upon by experts. The internal consistency of the measures was good (Cronbach's alpha: 0.803). Compared to novices, experts had smaller margin errors (0.79 mm vs 2.45 mm), lower carbonization (ΔE: 2.33 vs 8.70), faster resection times, and fewer grasping attempts (all P < 0.0001). Conclusion This user-friendly plant-derived simulation task is compatible with electrosurgery and can quantitatively assess proficiency in oral cancer resection. Using this task is expected to promote early acquisition of tumor resection skills and improve oncological safety.
- Open Access
- 24 July 2025
- Published by Elsevier in EJC Skin Cancer
- Vol. 3
Retrospective study of definitive therapy for head and neck mucosal melanoma: The RESUME study
- 24 July 2025
- Published by Elsevier in EJC Skin Cancer
- Vol. 3
Open AccessRetrospective study of definitive therapy for head and neck mucosal melanoma: The RESUME study